Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata

Last updated: August 19, 2024
Sponsor: Universidad Autonoma de Nuevo Leon
Overall Status: Active - Recruiting

Phase

N/A

Condition

Alopecia

Hair Loss

Treatment

Candida Albicans Antigen Injection

Clinical Study ID

NCT06564805
DE24-00008
  • Ages > 6
  • All Genders

Study Summary

The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of alopecia areata

  • SALT score of less than 50% extension

  • Has not received any topical or systemic treatment in the last month

  • Signed informed consent

Exclusion

Exclusion Criteria:

  • Any skin condition on the scalp (infectious, inflammatory or neoplastic) that couldmodify the clinical of trichoscopic features

  • Pregnancy or breast-feeding

  • Patients in medications that could cause hair loss as side-effects

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Candida Albicans Antigen Injection
Phase:
Study Start date:
August 20, 2024
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Hospital Universitario "Dr. José Eleuterio González"

    Monterrey, Nuevo León 64460
    Mexico

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.